BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30985385)

  • 21. Trends in the Prevalence and Incidence of Attention-Deficit/Hyperactivity Disorder Among Adults and Children of Different Racial and Ethnic Groups.
    Chung W; Jiang SF; Paksarian D; Nikolaidis A; Castellanos FX; Merikangas KR; Milham MP
    JAMA Netw Open; 2019 Nov; 2(11):e1914344. PubMed ID: 31675080
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The epidemiology of pharmacologically treated attention deficit hyperactivity disorder (ADHD) in children, adolescents and adults in UK primary care.
    McCarthy S; Wilton L; Murray ML; Hodgkins P; Asherson P; Wong IC
    BMC Pediatr; 2012 Jun; 12():78. PubMed ID: 22712630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
    Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
    Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antipsychotic Treatment Among Youths With Attention-Deficit/Hyperactivity Disorder.
    Sultan RS; Wang S; Crystal S; Olfson M
    JAMA Netw Open; 2019 Jul; 2(7):e197850. PubMed ID: 31348506
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stimulant therapy in children with attention-deficit/hyperactivity disorder and concomitant long QT syndrome: A safe combination?
    Rohatgi RK; Bos JM; Ackerman MJ
    Heart Rhythm; 2015 Aug; 12(8):1807-12. PubMed ID: 25956966
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Associations between Attention-Deficit Hyperactivity Disorder (ADHD) Treatment and Patient Nutritional Status and Height.
    Granato MF; Ferraro AA; Lellis DM; Casella EB
    Behav Neurol; 2018; 2018():7341529. PubMed ID: 30386441
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sex-Specific Long-Term Height and Body Mass Index Trajectories of Children Diagnosed with Attention-Deficit/Hyperactivity Disorder and Treated with Stimulants.
    Yackobovitch-Gavan M; Mimouni-Bloch A; Gabbay U; Carmi D; Goldstein B; Keinan-Boker L; Bloch S; Meyerovitch J
    J Pediatr; 2021 Nov; 238():296-304.e4. PubMed ID: 34293373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination therapy patterns and predictors of ADHD in commercially insured and Medicaid populations.
    Molife C; Bernauer MJ; Farr AM; Haynes VS; Kelsey D
    Postgrad Med; 2012 Sep; 124(5):7-22. PubMed ID: 23095422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Educational and Health Outcomes of Children Treated for Attention-Deficit/Hyperactivity Disorder.
    Fleming M; Fitton CA; Steiner MFC; McLay JS; Clark D; King A; Mackay DF; Pell JP
    JAMA Pediatr; 2017 Jul; 171(7):e170691. PubMed ID: 28459927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physician Office Visits for Attention-deficit/Hyperactivity Disorder in Children and Adolescents Aged 4-17 Years: United States, 2012-2013.
    Albert M; Rui P; Ashman JJ
    NCHS Data Brief; 2017 Jan; (269):1-8. PubMed ID: 28135186
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonmedical use of prescription stimulants among college students: associations with attention-deficit-hyperactivity disorder and polydrug use.
    Arria AM; Caldeira KM; O'Grady KE; Vincent KB; Johnson EP; Wish ED
    Pharmacotherapy; 2008 Feb; 28(2):156-69. PubMed ID: 18225963
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Influence of Age, Gender, and Living Circumstances on Patterns of Attention-Deficit/Hyperactivity Disorder Medication Use in Children and Adolescents With or Without Intellectual Disabilities.
    Osunsanmi S; Turk J
    J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):828-834. PubMed ID: 26982546
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Injury prevention by medication among children with attention-deficit/hyperactivity disorder: a case-only study.
    Mikolajczyk R; Horn J; Schmedt N; Langner I; Lindemann C; Garbe E
    JAMA Pediatr; 2015 Apr; 169(4):391-5. PubMed ID: 25686215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Medication Use for Attention-Deficit/Hyperactivity Disorder and Risk of Motor Vehicle Crashes.
    Chang Z; Quinn PD; Hur K; Gibbons RD; Sjölander A; Larsson H; D'Onofrio BM
    JAMA Psychiatry; 2017 Jun; 74(6):597-603. PubMed ID: 28492937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploratory analysis of early treatment discontinuation and clinical outcomes of patients with attention-deficit/hyperactivity disorder.
    Wu SH; Wang K; Chen Y; Wang WQ; Wang F; Montgomery W; Treuer T
    Asia Pac Psychiatry; 2017 Mar; 9(1):. PubMed ID: 26663807
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of adverse events in non-randomised studies.
    Storebø OJ; Pedersen N; Ramstad E; Kielsholm ML; Nielsen SS; Krogh HB; Moreira-Maia CR; Magnusson FL; Holmskov M; Gerner T; Skoog M; Rosendal S; Groth C; Gillies D; Buch Rasmussen K; Gauci D; Zwi M; Kirubakaran R; Håkonsen SJ; Aagaard L; Simonsen E; Gluud C
    Cochrane Database Syst Rev; 2018 May; 5(5):CD012069. PubMed ID: 29744873
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comorbidities in ADHD children treated with methylphenidate: a database study.
    Kraut AA; Langner I; Lindemann C; Banaschewski T; Petermann U; Petermann F; Mikolajczyk RT; Garbe E
    BMC Psychiatry; 2013 Jan; 13():11. PubMed ID: 23294623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medication costs to private insurers of diversion of medications for attention-deficit hyperactivity disorder.
    Aldridge AP; Kroutil LA; Cowell AJ; Reeves DB; Van Brunt DL
    Pharmacoeconomics; 2011 Jul; 29(7):621-35. PubMed ID: 21473655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testicular Function After Long-Term Methylphenidate Treatment in Boys with Attention-Deficit/Hyperactivity Disorder.
    Wang LJ; Lee SY; Chou WJ; Lee MJ; Tsai CS; Lee TL; Yang CJ; Yang KC; Chen CK; Shyu YC
    J Child Adolesc Psychopharmacol; 2019 Aug; 29(6):433-438. PubMed ID: 30575416
    [No Abstract]   [Full Text] [Related]  

  • 40. Age-specific prevalence, incidence of new diagnoses, and drug treatment of attention-deficit/hyperactivity disorder in Germany.
    Lindemann C; Langner I; Kraut AA; Banaschewski T; Schad-Hansjosten T; Petermann U; Petermann F; Schreyer-Mehlhop I; Garbe E; Mikolajczyk RT
    J Child Adolesc Psychopharmacol; 2012 Aug; 22(4):307-14. PubMed ID: 22856384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.